首页> 外文期刊>BMC Cancer >Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B
【24h】

Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B

机译:在巴塞罗那临床肝癌(BCLC)0或B期的肝细胞癌患者中,微血管浸润的临床价值有限

获取原文
           

摘要

Background Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can provide prognostic information for patients at a specific tumor stage. Methods Consecutive HCC patients who underwent curative resection in years of 2007 and 2008 (discovery cohort) were enrolled in this retrospective study. Patients were stratified by the Barcelona Clinic Liver Cancer (BCLC) staging system. The prognostic significance of MVI for overall survival (OS) and recurrence-free survival (RFS) was studied in each subgroup. The clinical significance of MVI was validated in another cohort of patients underwent curative surgery in the year of 2006 (validation cohort). Results Of the 1540 patients in the discovery cohort, 389 (25.3%) patients had detectable MVI. Occurrence rates of MVI in the BCLC stage 0, A, and B subgroups were 12.4, 26.2, and 34.4%, respectively. In univariate analysis, MVI was associated with poor OS and RFS ( P Conclusions MVI has limited prognostic value for HCC patients at BCLC stages 0 and B. For those at stage A, MVI was associated with patient survival and may help to select patients with high risk of disease recurrence.
机译:背景技术微血管浸润(MVI)被认为是治愈性肝癌(HCC)患者预后不良的预后因素。然而,尚不清楚MVI是否可以为特定肿瘤阶段的患者提供预后信息。方法回顾性分析2007年和2008年连续进行手术切除的HCC患者(发现队列)。通过巴塞罗那临床肝癌(BCLC)分期系统对患者进行分层。在每个亚组中研究了MVI对总生存期(OS)和无复发生存期(RFS)的预后意义。 MVI的临床意义在2006年的另一组接受手术治疗的患者中得到了验证(验证队列)。结果发现队列中的1540名患者中,有389名(25.3%)患者可检测到MVI。在BCLC阶段0,A和B亚组中,MVI的发生率分别为12.4%,26.2%和34.4%。在单因素分析中,MVI与OS和RFS差有关(P结论MVI对BCLC 0和B期肝癌患者的预后价值有限。对于A期患者,MVI与患者生存率相关,可能有助于选择高危患者疾病复发的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号